Fezolinetant making waves for VMS

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.

A recent study highlights worsened walking and motor skills in postmenopausal women with multiple sclerosis, shedding light on the need to determine hormone therapy benefits.

In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.

The OASIS 4 clinical trial showed successful reductions in the frequency and severity of hot flashes caused by adjuvant endocrine therapy used in breast cancer management.

A recent study highlights improved sexual function and reduced distress among nonheterosexual women during menopause compared to their heterosexual counterparts, shedding light on how sexual identity impacts well-being.